MAVYRET
mavyret.com
Actively hiring
Medical Laboratories
Prescription Drugs
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Official MAVYRET (glecaprevir/pibrentasvir) site from AbbVie Inc. for patients. Learn about the use, safety and efficacy of MAVYRET. View full prescribing information.
News
Mavyret approved for acute HCV
FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from the manufacturer, AbbVie.
Read more
Report
Report
U.S. FDA Approves Expanded Indication for AbbVie
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved for the treatment of adu
Read more
Report
Mavyret cost 2026: Coupons and more
Mavyret is used to treat chronic hepatitis C in adults and certain children. Find out about cost, financial and insurance assistance, and more.
Read more
Report
Mavyret side effects: What they are and how to manage them
Mavyret is a prescription drug for hepatitis C (hep C). Learn about the common, mild, and serious side effects the drug can cause and how to manage them.
Read more
Report
Pro access
Upgrade to see all 11 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.